GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fosun Pharmaceutical (Group) Co Ltd (STU:08HH) » Definitions » Net Income Including Noncontrolling Interests

Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH) Net Income Including Noncontrolling Interests : €472 Mil (TTM As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is Shanghai Fosun Pharmaceutical (Group) Co Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Shanghai Fosun Pharmaceutical (Group) Co's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2025 was €120 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 was €472 Mil.


Shanghai Fosun Pharmaceutical (Group) Co Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Fosun Pharmaceutical (Group) Co Net Income Including Noncontrolling Interests Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only 495.26 691.44 534.51 371.81 460.72

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 100.44 97.77 123.36 130.37 120.14

Shanghai Fosun Pharmaceutical (Group) Co Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €472 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Fosun Pharmaceutical (Group) Co Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Shanghai Fosun Pharmaceutical (Group) Co's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Fosun Pharmaceutical (Group) Co Business Description

Address
No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, and sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.

Shanghai Fosun Pharmaceutical (Group) Co Headlines

No Headlines